Ischaemic heart disease

CANTOS validates role of inflammation in heart disease

–Modest treatment effect of canakinumab may limit clinical role in heart disease, but strong anti-cancer signal sparks interest. Despite questions about its clinical importance, the CANTOS trial is being hailed by experts for finally validating the role of inflammation in heart disease. The cardiovascular benefits in the trial were real but modest. Even more exciting, ...

Already a member?

Login to keep reading.

© 2021 the limbic